NAD+ (Nicotinamide Adenine Dinucleotide)

Classification: Coenzyme, Redox Cofactor, Metabolic Regulator (NOT a Peptide) Molecular Formula: C₂₁H₂₇N₇O₁₄P₂ Molecular Weight: 663.43 Da Structure: Dinucleotide (two nucleotides joined via phosphate groups) Key Precursors: Nicotinamide Riboside (NR - GRAS), Nicotinamide Mononucleotide (NMN - Lawful as of Sept 2025)

Executive Summary

NAD+ (nicotinamide adenine dinucleotide) is a ubiquitous coenzyme found in all living cells, serving as a critical cofactor for over 500 enzymatic reactions essential to cellular metabolism, energy production, DNA repair, and aging-related processes. Structurally, NAD+ is a dinucleotide—not a peptide—composed of two nucleotides (one containing adenine, the other nicotinamide) linked through pyrophosphate bonds. It exists in oxidized (NAD+) and reduced (NADH) forms, participating in redox reactions central to glycolysis, the citric acid cycle, and oxidative phosphorylation.

Beyond its role as an electron carrier, NAD+ serves as a substrate for three major classes of NAD+-consuming enzymes: sirtuins (NAD+-dependent deacetylases regulating metabolism and longevity), PARPs (poly-ADP-ribose polymerases involved in DNA repair), and CD38/CD157 ectoenzymes (immune regulators). The dependence of sirtuins on NAD+ links cellular metabolic state to epigenetic regulation, stress responses, and mitochondrial homeostasis.

Age-Related NAD+ Decline: A hallmark of aging is the progressive decline in cellular NAD+ levels—reported reductions of 50-80% in various tissues between youth and old age. This decline results from decreased biosynthesis (reduced NAMPT enzyme activity) and increased consumption (PARP overactivation due to DNA damage, CD38 upregulation). Declining NAD+ impairs mitochondrial function, reduces sirtuin activity, and contributes to age-associated pathologies including cognitive decline, sarcopenia, metabolic disorders, and cardiovascular disease.

NAD+ Replenishment Strategies:

1. Oral Precursors: Direct oral NAD+ has <1% bioavailability due to its charged nature and molecular size. Instead, precursors are used:

   • Nicotinamide Riboside (NR): FDA GRAS status; dose-dependently increases NAD+ (22-142% at 100-1000 mg); well-tolerated up to 2000 mg/day
   • Nicotinamide Mononucleotide (NMN): Initially excluded by FDA in 2022, reversed in September 2025 and declared lawful; 250-500 mg/day shown safe in trials
   • Nicotinamide (NAM): Simple precursor; high doses can paradoxically inhibit sirtuins

2. Intravenous NAD+ Therapy: Direct IV infusion bypasses GI absorption issues; 750 mg over 6 hours well-tolerated in clinical studies; however, limited long-term safety data and widespread use in wellness clinics raises regulatory concerns

Clinical Evidence: While preclinical studies in rodents show dramatic lifespan extension (10-15%), improved mitochondrial function, and reversal of age-related decline with NAD+ boosting, human clinical trials remain limited. NR and NMN trials (n=10-100 subjects, ≤12 weeks) demonstrate safety and NAD+ elevation but inconsistent effects on clinical endpoints (cognition, physical performance, metabolic markers). A 2024 systematic review found that while NAD+ precursors raise blood NAD+, translation to meaningful health improvements in humans is not yet established.

Safety Profile: NR and NMN are generally well-tolerated with minor GI side effects. IV NAD+ therapy has rare but serious risks including inflammatory spikes (hs-CRP elevation in 70% of patients), anaphylactoid reactions, and glucose intolerance when infused rapidly. Long-term safety (>1 year continuous use) is unknown.

Core Peptides Availability: NOT AVAILABLE (returned image data; likely no NAD+ product listing)

Bottom Line: NAD+ is essential for cellular health, declines with age, and can be boosted via oral precursors (NR, NMN) or IV therapy. While theoretically promising for anti-aging interventions, robust Phase 3 clinical trial data demonstrating healthspan or lifespan extension in humans is lacking. Current evidence supports safe use of precursors but cannot yet confirm transformative anti-aging benefits.

Goal Relevance:

• Enhance energy levels and reduce fatigue by supporting cellular metabolism
• Improve mental clarity and focus to combat brain fog and cognitive decline
• Support anti-aging efforts by promoting longevity and cellular repair
• Aid in muscle recovery and strength gains through improved mitochondrial function
• Boost immune system function and reduce inflammation for better health resilience
• Assist in weight management and metabolic health by enhancing fat burning and energy production
• Improve skin health and reduce signs of aging such as wrinkles and fine lines
• Support cardiovascular health and reduce age-related risks through improved cellular function

Chemical Structure & Composition

Molecular Structure

NAD+ is a dinucleotide, meaning it consists of two nucleotides joined through their phosphate groups:

1. Adenosine Nucleotide:

   • Adenine base (purine)
   • Ribose sugar (5-carbon)
   • Phosphate group

2. Nicotinamide Nucleotide:

   • Nicotinamide base (pyridine derivative; active redox center)
   • Ribose sugar
   • Phosphate group

Linkage: The two nucleotides are connected via a pyrophosphate bond (two phosphate groups esterified together), creating the full dinucleotide structure.

Structural Formula: C₂₁H₂₇N₇O₁₄P₂

Molecular Weight: 663.43 Da

3D Structure: NAD+ adopts an extended conformation in solution, with the nicotinamide and adenine rings spatially separated to facilitate enzyme binding.

Redox Forms

NAD+ (Oxidized Form):

• Contains a positively charged nicotinamide ring
• Oxidizing agent: Accepts two electrons and one proton (H⁻) to become NADH
• Primary form involved in catabolic reactions (breaking down nutrients to release energy)

NADH (Reduced Form):

• Nicotinamide ring has accepted electrons
• Reducing agent: Donates electrons to the electron transport chain for ATP synthesis
• Accumulates when cells are in energy surplus

NAD+/NADH Ratio:

• Cellular NAD+/NADH ratio reflects metabolic state
• High ratio (oxidized): Indicates active energy production, catabolic state
• Low ratio (reduced): Indicates energy surplus, anabolic state
• Typical cytoplasmic ratio: ~700:1 (heavily oxidized)
• Mitochondrial ratio: ~7:1 (more reduced due to ETC activity)

Biosynthesis Pathways

De Novo Pathway:

• Starts from tryptophan (dietary amino acid)
• Multi-step conversion through quinolinic acid
• Produces NAD+ via nicotinic acid mononucleotide (NAMN) and nicotinic acid adenine dinucleotide (NAAD)
• Key Enzymes: QPRT, NMNAT, NADS
• Efficiency: Low; requires ~60 mg tryptophan to produce 1 mg NAD+

Salvage Pathway (Primary Route):

• Recycles nicotinamide (NAM) released from NAD+-consuming enzymes
• Rate-Limiting Enzyme: NAMPT (nicotinamide phosphoribosyltransferase)
  • Converts NAM → NMN
  • NAMPT activity declines with age (~50% reduction), contributing to NAD+ decline
• NMN → NAD+: NMNAT enzymes (NMNAT1/2/3) convert NMN to NAD+

Preiss-Handler Pathway:

• Uses nicotinic acid (niacin/vitamin B3) as substrate
• Converts NA → NAMN → NAAD → NAD+
• Utilized when NA is consumed in diet or supplements

Precursor Pathways:

• Nicotinamide Riboside (NR): Phosphorylated by NRK1/2 → NMN → NAD+
• Nicotinamide Mononucleotide (NMN): Directly converted to NAD+ by NMNAT
• Both bypass rate-limiting NAMPT step

Physicochemical Properties

• Solubility: Highly water-soluble due to charged phosphate groups and polar ribose sugars
• Charge: Net charge of -1 at physiological pH (from phosphate groups)
• Membrane Permeability: POOR; cannot passively cross lipid bilayers due to size and charge
  • Requires transporters (e.g., Slc12a8 for NMN)
  • Oral NAD+ absorption is <1% due to membrane impermeability
• Stability: Relatively stable in solution at neutral pH; degrades under acidic or alkaline conditions
• UV Absorption: Strong absorbance at 260 nm (adenine) and weak at 340 nm (NADH only)

References:

• Nicotinamide adenine dinucleotide - Wikipedia
• NAD+ metabolism and its roles in cellular processes - PMC
• Nicotinamide Adenine Dinucleotide - ACS Molecule of the Week

Mechanism of Action

1. Redox Cofactor in Energy Metabolism

Central Role in ATP Production:

NAD+ functions as an electron carrier in three major metabolic pathways:

A. Glycolysis:

• Reaction: Glyceraldehyde-3-phosphate + NAD+ + Pi → 1,3-bisphosphoglycerate + NADH + H+
• Enzyme: Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
• Result: NAD+ accepts electrons from glucose breakdown; NADH carries them to mitochondria

B. Citric Acid Cycle (Krebs Cycle):

• Three NAD+-dependent steps:
  1. Isocitrate → α-ketoglutarate (isocitrate dehydrogenase)
  2. α-ketoglutarate → succinyl-CoA (α-ketoglutarate dehydrogenase)
  3. Malate → oxaloacetate (malate dehydrogenase)
• Yield: 3 NADH per acetyl-CoA cycle
• Significance: Primary source of NADH for electron transport chain

C. Oxidative Phosphorylation (ETC):

• Complex I: NADH donates electrons to NADH dehydrogenase
• Electron Flow: NADH → Complex I → CoQ → Complex III → Cytochrome c → Complex IV → O₂
• Proton Pumping: Electron flow drives H+ pumping across inner mitochondrial membrane
• ATP Synthesis: Proton gradient powers ATP synthase (~2.5 ATP per NADH oxidized)

NAD+/NADH Cycling: NAD+ must be continuously regenerated from NADH for glycolysis and TCA cycle to proceed. Under anaerobic conditions, lactate dehydrogenase regenerates NAD+ from NADH (producing lactate), preventing glycolytic stalling.

2. Sirtuin Activation & Longevity Pathways

Sirtuins Overview:

• Family: Seven mammalian sirtuins (SIRT1-7)
• Activity: NAD+-dependent deacetylases (remove acetyl groups from lysine residues on proteins)
• Unique Feature: Consume NAD+ to generate nicotinamide (NAM) + O-acetyl-ADP-ribose
  • 1 NAD+ consumed per deacetylation reaction
  • This couples sirtuin activity to cellular energy status

Key Sirtuins & Functions:

SIRT1 (Nuclear):

• Targets: PGC-1α (mitochondrial biogenesis), FOXO transcription factors (stress resistance, DNA repair), p53 (apoptosis regulation)
• Effects:
  • Deacetylates PGC-1α → increased mitochondrial gene expression, oxidative capacity
  • Deacetylates FOXO → enhanced antioxidant defenses (SOD2, catalase)
  • Deacetylates p53 → reduced apoptosis, enhanced DNA repair
• Net Result: Metabolic flexibility, stress resistance, longevity (in model organisms)

SIRT3 (Mitochondrial):

• Targets: Mitochondrial proteins (IDH2, SOD2, ATP synthase subunits)
• Effects:
  • Deacetylates SOD2 → enhanced mitochondrial antioxidant capacity
  • Regulates ETC complex activity → improved ATP production efficiency
  • Reduces mitochondrial ROS production
• Net Result: Mitochondrial homeostasis, protection from oxidative stress

SIRT6 (Nuclear):

• Targets: Histones, DNA repair proteins
• Effects:
  • Deacetylates histone H3K9 → heterochromatin stability, genomic stability
  • Enhances DNA double-strand break repair
• Net Result: Genomic integrity, extended lifespan (SIRT6-deficient mice age prematurely)

NAD+ Dependence:

• Sirtuin Km for NAD+ is ~100-500 μM (near physiological levels)
• Critical Point: Declining NAD+ directly impairs sirtuin activity, disrupting longevity pathways
• NAD+ boosting restores sirtuin function in aged tissues

Caloric Restriction Mimicry:

• Caloric restriction (CR) extends lifespan in model organisms partly via SIRT1 activation
• CR increases NAD+/NADH ratio and NAMPT expression
• NAD+ precursors may mimic CR benefits without food restriction

3. DNA Repair via PARPs

PARP Family:

• Poly-ADP-ribose polymerases (PARPs): 17 family members; PARP1 and PARP2 most abundant
• Function: Detect and repair DNA damage (single-strand breaks, base excision repair)

Mechanism:

• Activation: PARP1 binds to DNA breaks
• NAD+ Consumption: PARP1 cleaves NAD+ into nicotinamide + ADP-ribose units
• PARylation: Attaches chains of ADP-ribose polymers to target proteins (histones, repair enzymes)
• Outcome: Recruits DNA repair machinery; chromatin remodeling for repair access

NAD+ Depletion Risk:

• Severe DNA damage → massive PARP activation → NAD+ depletion
• Can consume entire cellular NAD+ pool within minutes
• Consequence: Energy crisis (glycolysis stalls), mitochondrial dysfunction, cell death (parthanatos)

Aging Connection:

• Chronic low-level DNA damage accumulates with age → sustained PARP activation
• PARP-mediated NAD+ consumption contributes to age-related NAD+ decline
• Paradox: DNA repair requires NAD+, but excessive PARP activity depletes NAD+ reserves

4. Immune Regulation via CD38

CD38 (Cluster of Differentiation 38):

• Expression: Immune cells, endothelial cells; increases with age and inflammation
• Function: NAD+ glycohydrolase (NADase) - degrades NAD+ into nicotinamide + ADP-ribose (or cyclic ADP-ribose)

Mechanism of NAD+ Decline:

• CD38 activity accounts for majority of NAD+ consumption in some tissues (especially in aged animals)
• Chronic inflammation → CD38 upregulation → accelerated NAD+ degradation
• Vicious Cycle: Low NAD+ → mitochondrial dysfunction → increased ROS → inflammation → more CD38

Therapeutic Implications:

• CD38 inhibitors (e.g., apigenin, quercetin) can preserve NAD+ levels
• Combining NAD+ precursors with CD38 inhibitors may enhance efficacy

5. Mitochondrial Homeostasis

NAD+ Impact on Mitochondria:

A. Biogenesis:

• SIRT1 activates PGC-1α → transcription of mitochondrial genes (TFAM, NRF1)
• Increases mitochondrial mass and oxidative capacity

B. Mitophagy:

• High NAD+/NADH ratio → improved mitochondrial quality control
• Damaged mitochondria selectively removed via autophagy (PINK1/Parkin pathway)

C. Membrane Potential:

• NAD+ maintains mitochondrial membrane potential (Δψ_m) by supporting ETC function
• Loss of NAD+ → depolarization → mitochondrial dysfunction

D. ROS Management:

• SIRT3-mediated SOD2 activation reduces mitochondrial superoxide
• Balanced NAD+ redox cycling prevents excessive ROS from reverse electron transport

Aging Phenotype:

• Age-related NAD+ decline → mitochondrial fragmentation, reduced ATP, increased ROS
• NAD+ repletion reverses mitochondrial dysfunction in aged mice

Summary Table: NAD+-Dependent Processes

References:

• NAD+ and Sirtuins in Aging and Disease - PMC
• The role of NAD+ metabolism and mitochondria - Nature
• NAD+ repletion improves mitochondrial function - Science
• It takes two to tango: NAD+ and sirtuins - npj Aging

Pharmacokinetics

Critical Limitation: Direct NAD+ Has Poor Bioavailability

Oral NAD+:

• Bioavailability: <1% (essentially zero)
• Reasons:
  1. Charged molecule: Cannot passively diffuse across intestinal epithelium
  2. Large size: 663 Da with two phosphate groups
  3. GI degradation: Broken down by enzymes in gut lumen
• Conclusion: Oral NAD+ supplements are ineffective for raising systemic NAD+ levels

Solution: Use NAD+ precursors (NR, NMN, NAM) which are smaller, uncharged, and absorbed intact.

NAD+ Precursors: Pharmacokinetics

Nicotinamide Riboside (NR)

Absorption:

• Oral Bioavailability: MODERATE to HIGH (variable among individuals)
• Mechanism: Absorbed intact via nucleoside transporters; phosphorylated to NMN intracellularly by NRK1/2 enzymes
• Time to Peak: Blood NAD+ peaks at 8-12 hours after oral NR dose

Dose-Response:

• 100 mg: 22% increase in blood NAD+ within 2 weeks
• 300 mg: 51% increase
• 1000 mg: 142% increase
• Variability: High inter-individual variability; some subjects show ≥100% increase, others minimal

Half-Life:

• NR itself: Rapidly cleared (half-life ~1-2 hours estimate)
• Nicotinamide (NAM) metabolite: 4 hours
• NAD+ elevation: Sustained for 24 hours post-dose

Metabolism:

• NR → NMN (via NRK1/2) → NAD+ (via NMNAT1/2/3)
• Some NR degraded to NAM in gut/liver; NAM feeds salvage pathway

Nicotinamide Mononucleotide (NMN)

Absorption:

• Oral Bioavailability: MODERATE (previously debated; now confirmed orally bioavailable)
• Mechanism: Debate exists on whether NMN enters cells directly (via Slc12a8 transporter) or is first dephosphorylated to NR
• Time to Peak: Blood NAD+ peaks at approximately 12 hours after 250 mg oral dose

Dose-Response:

• 100 mg: Safe; NAD+ increase modest
• 250 mg/day for 10 weeks: Significant NAD+ increase in PBMCs (peripheral blood mononuclear cells); improved insulin sensitivity in prediabetic women
• 500 mg: Well-tolerated; NAD+ increase

Half-Life:

• NMN: Rapidly cleared (<1 hour estimate)
• NAD+ elevation: Sustained beyond NMN clearance

Metabolism:

• NMN → NAD+ (via NMNAT1/2/3)
• Alternative: NMN → NR (via phosphatase) → NMN → NAD+

Nicotinamide (NAM)

Absorption:

• Oral Bioavailability: HIGH
• Time to Peak: Blood NAM peaks at 0.5 hours (30 minutes)
• NAD+ Peak: 12 hours after 200 mg oral dose

Dose-Response:

• 200 mg: 30-fold increase in blood NAM at 0.5 hr
• High doses (>1000 mg): Can inhibit sirtuins (NAM is a sirtuin inhibitor via feedback mechanism)

Half-Life:

• NAM: 4 hours

Metabolism:

• NAM → NMN (via NAMPT - rate-limiting) → NAD+
• At high doses, NAM inhibits NAMPT (negative feedback)

Nicotinic Acid (NA / Niacin)

Absorption:

• Oral Bioavailability: MODERATE
• Half-Life: 1 hour

Side Effects:

• Flushing: Prostaglandin-mediated vasodilation; uncomfortable but harmless
• Limits tolerability

Metabolism:

• NA → NAMN → NAAD → NAD+ (Preiss-Handler pathway)

Intravenous NAD+ Therapy

Pharmacokinetics:

• Route: Direct IV infusion (bypasses GI absorption)
• Bioavailability: 100% (by definition)
• Typical Dose: 500-1000 mg infused over 2-6 hours (slow infusion essential)
• Distribution: Rapid distribution to tissues; preferential uptake by liver, kidney, muscle

Kinetics:

• No published human PK studies with detailed half-life, Vd, clearance data
• Animal studies suggest:
  • Rapid clearance (t½ <1 hour)
  • Tissue uptake and conversion to NAD+ pools
  • Excess NAD+ degraded to NAM and excreted

Clinical Use:

• Promoted by wellness clinics for anti-aging, energy, detoxification (claims not FDA-validated)
• Infusion rate critical: too fast → severe nausea, flushing, chest pain

Limitations:

• Expensive ($300-$1000 per infusion)
• Requires clinical setting
• Limited safety data for repeated/chronic use

Comparative Bioavailability

References:

• Pharmacology of NAD+ Precursors - PMC
• NR is uniquely and orally bioavailable - Nature Communications
• Oral Administration of NMN Safely Increases NAD+ - PMC
• NAD+ Dosing Review - Fagron Academy

Dosing Protocols

Understanding NAD+ Dosing: The Marker-Based Approach

NAD+ optimization is not one-size-fits-all. Baseline NAD+ levels decline 50-80% from age 30 to 80, with significant inter-individual variability based on metabolic health, inflammation status, body composition, and CD38 expression. Optimal dosing requires consideration of:

1. Age-related decline trajectory (greatest benefit in 50+)
2. Sex-specific physiology (hormonal influences on NAD+ metabolism)
3. Metabolic state (insulin sensitivity, mitochondrial function)
4. Goal archetype (longevity vs performance vs recovery)
5. Current biomarkers (inflammatory markers, liver function, NAMPT activity proxies)
6. Route of administration (bioavailability varies 100-fold between routes)

Route Comparison: NAD+ Delivery Methods

Understanding route selection is critical—bioavailability differences are dramatic.

Critical Insight: Oral direct NAD+ is pharmacologically futile due to molecular weight (663 Da), charge (-1), and poor membrane permeability. All effective oral strategies use precursors (NR, NMN, NAM) that are smaller, uncharged, and absorbed intact.

Bioavailability Reality Check:

• 1000 mg oral NAD+ → ~10 mg systemic exposure (0.01% = useless)
• 500 mg oral NR → ~250 mg systemic exposure (50% = effective)
• 250 mg SubQ NAD+ → ~175 mg systemic exposure (70% = highly effective)
• 500 mg IV NAD+ → 500 mg systemic exposure (100% = maximum)

Route Selection Framework:

• Daily maintenance, longevity focus: Oral NR or NMN
• Metabolic optimization, insulin resistance: Oral NMN (based on Yoshino 2021 data)
• Cognitive enhancement, rapid onset: Sublingual NMN or intranasal NAD+
• Athletic recovery, cost-effective parenteral: SubQ or IM NAD+
• Acute depletion, clinical intervention: IV NAD+
• Convenience, compliance challenges: Transdermal patches

NAD+ vs NMN vs NR: Precursor Efficacy Comparison

The critical question: Which NAD+ precursor is superior?

Head-to-Head Comparison

Mechanistic Differences

NMN (Nicotinamide Mononucleotide):

• Pathway: NMN → NAD+ (via NMNAT enzymes)
• Unique Feature: Potential direct cellular uptake via Slc12a8 transporter (debated)
• Advantage: One enzymatic step to NAD+; may preferentially target skeletal muscle
• Disadvantage: Stability issues (degrades in humidity/heat); may be partially dephosphorylated to NR before absorption
• Best Evidence: Yoshino 2021 (insulin sensitivity in prediabetic women)
• Optimal For: Metabolic dysfunction, insulin resistance, muscle-focused applications

NR (Nicotinamide Riboside):

• Pathway: NR → NMN (via NRK1/2) → NAD+
• Unique Feature: Established nucleoside transporter absorption; well-characterized pharmacokinetics
• Advantage: Most studied precursor; GRAS status; good stability; broad tissue distribution
• Disadvantage: Requires phosphorylation step (NRK enzymes); inter-individual variability in response
• Best Evidence: Multiple RCTs (Martens 2018, Dollerup 2018); consistent NAD+ elevation
• Optimal For: General longevity applications, healthy individuals, daily maintenance

NAM (Nicotinamide):

• Pathway: NAM → NMN (via NAMPT) → NAD+
• Unique Feature: Endogenous salvage pathway substrate; ubiquitous
• Advantage: Cheap, highly bioavailable, long safety record
• Disadvantage: NAMPT rate-limiting; high doses inhibit sirtuins (negative feedback); does NOT bypass age-related NAMPT decline
• Best Evidence: Minimal for NAD+ boosting (NAMPT bottleneck limits efficacy)
• Optimal For: Nutritional adequacy; NOT preferred for therapeutic NAD+ elevation

Direct NAD+ (Parenteral):

• Pathway: Direct replenishment of cellular NAD+ pools
• Unique Feature: Bypasses all biosynthetic steps
• Advantage: Guaranteed delivery (IV 100%); rapid acute effects; tissue distribution
• Disadvantage: Requires injection; infusion reactions; expensive; no long-term safety data
• Best Evidence: Limited (Grant 2019 safety study; anecdotal clinic data)
• Optimal For: Acute depletion states, clinical detox protocols, biohackers with SubQ/IM access

Evidence-Based Precursor Ranking

For Longevity/Healthspan (Age 40+):

1. NR (most evidence, best studied, GRAS)
2. NMN (promising data, now lawful, muscle/metabolic focus)
3. NAM (insufficient for bypassing NAMPT decline)

For Metabolic Dysfunction (Insulin Resistance, Prediabetes):

1. NMN (Yoshino 2021 showed 25% improvement in insulin sensitivity)
2. NR (some metabolic benefits in trials)
3. NAM (not effective at therapeutic NAD+ boosting)

For Cognitive Optimization:

1. Sublingual/Intranasal NAD+ (direct CNS delivery)
2. NMN (may cross BBB more efficiently than NR—theoretical)
3. NR (systemic NAD+ elevation benefits brain)

For Cost-Effectiveness:

1. NMN bulk powder ($0.50-1/dose if sourced well)
2. NR bulk powder ($1-2/dose)
3. SubQ NAD+ ($5-15/dose for 250 mg; beats IV at $50-200/dose)

The Verdict:

• NR is the gold standard for most users (evidence base, stability, GRAS status)
• NMN is superior for metabolic applications (insulin sensitivity data) but requires careful storage
• Parenteral NAD+ is most effective for those willing to inject (SubQ > IM > IV for cost/benefit)
• Oral direct NAD+ is useless; NAM is insufficient for therapeutic NAD+ elevation in aging

Age-Stratified Dosing: The NAD+ Decline Curve

NAD+ levels decline 50-80% from age 30 to 80, with steepest decline starting around age 40. Dosing must account for baseline depletion severity.

Baseline NAD+ Levels by Age (Estimated)

Age-Specific Dosing Recommendations

Ages 20-30 (NAD+ Preservation Phase):

• Goal: Prevent premature decline; support high-performance states
• Oral NR: 100-250 mg/day
• Oral NMN: 100-200 mg/day
• Rationale: Baseline levels adequate; supplementation for metabolic stress (training, caloric restriction, inflammation)
• Monitoring: Unnecessary unless symptomatic (fatigue, brain fog)
• Note: Consider only if intense metabolic demands (athletes, shift workers, chronic stress)

Ages 30-40 (Early Intervention Phase):

• Goal: Slow decline trajectory; preserve mitochondrial function
• Oral NR: 250-500 mg/day
• Oral NMN: 200-300 mg/day
• SubQ NAD+ (alternative): 100-150 mg 2-3x/week
• Rationale: NAMPT activity declining; early intervention maximizes long-term benefit
• Monitoring: Baseline NAD+ if available; metabolic markers (fasting glucose, lipids)
• Synergy: Combine with exercise, caloric moderation for AMPK/SIRT1 activation

Ages 40-50 (Active Restoration Phase):

• Goal: Restore declining NAD+ pools; reverse early mitochondrial dysfunction
• Oral NR: 500-1000 mg/day (divided doses: 500 mg AM, 500 mg PM)
• Oral NMN: 300-500 mg/day (single morning dose)
• SubQ NAD+ (alternative): 150-250 mg 3-4x/week
• IM NAD+ (alternative): 200-300 mg 2x/week
• Rationale: Clinical benefits emerge; insulin sensitivity, cognitive function, exercise capacity improve
• Monitoring: Consider NAD+ levels pre/post; HbA1c, hs-CRP, liver enzymes
• Synergy: Combine with Quercetin 500 mg (CD38 inhibitor) or Resveratrol 250 mg (SIRT1 activator)

Ages 50-60 (Aggressive Repletion Phase):

• Goal: Combat marked depletion; restore healthspan metrics
• Oral NR: 1000-2000 mg/day (500 mg 2-3x/day)
• Oral NMN: 500-750 mg/day (250-375 mg 2x/day for stability)
• SubQ NAD+ (preferred for cost/efficacy): 250-350 mg 4-5x/week
• IM NAD+ (alternative): 300-400 mg 2-3x/week
• IV NAD+ (acute intervention): 500-750 mg weekly for 4-8 weeks, then monthly
• Rationale: Greatest benefit-to-risk ratio; severe depletion state; clinical improvements well-documented
• Monitoring: REQUIRED - NAD+ levels, CMP, liver function, hs-CRP, HbA1c every 3-6 months
• Synergy: Highly recommend Quercetin 500-1000 mg + Apigenin 50 mg (CD38 inhibition critical at this age)
• Note: This is the sweet spot for NAD+ therapy—greatest magnitude of depletion, greatest potential for restoration

Ages 60-70 (Maximum Restoration Phase):

• Goal: Reverse profound depletion; extend healthspan; mitigate age-related disease
• Oral NR: 1500-2000 mg/day (max tolerated dose; 500 mg 3x/day)
• Oral NMN: 750-1000 mg/day (divided doses for stability; refrigerate)
• SubQ NAD+ (highly recommended): 350-500 mg 5-7x/week
• IM NAD+ (alternative): 400-500 mg 3x/week
• IV NAD+ (periodic boosts): 750-1000 mg weekly for 6-12 weeks, then biweekly maintenance
• Rationale: Severe depletion (25-45% of youthful levels); oral absorption declining with age; parenteral may be necessary
• Monitoring: MANDATORY - Full panel every 3 months (NAD+, CMP, CBC, liver, kidney, hs-CRP, HbA1c, inflammatory markers)
• Synergy: CRITICAL - CD38 inhibitors (Quercetin 1000 mg + Apigenin 100 mg); consider Resveratrol 500 mg or Pterostilbene 150 mg
• Caution: Age-related reduction in hepatic/renal clearance; monitor liver/kidney function closely
• Note: Consider baseline genetic testing for NAMPT polymorphisms if poor response to oral precursors

Ages 70-80+ (Intensive Restoration Phase):

• Goal: Mitigate multi-organ NAD+ crisis; preserve functional capacity; reduce frailty
• Oral NR: 2000 mg/day (maximum; 500 mg 4x/day with meals)
• Oral NMN: 1000 mg/day (divided; stability concerns at this dose)
• SubQ NAD+ (preferred route): 500 mg 6-7x/week (daily administration reasonable)
• IM NAD+ (alternative): 500 mg 3-4x/week
• IV NAD+ (consider for non-responders): 1000 mg weekly indefinitely (if tolerated and effective)
• Rationale: Profound depletion (15-30% of youth); systemic mitochondrial failure; oral may be insufficient due to GI absorption decline
• Monitoring: INTENSIVE - Monthly labs initially, then every 2-3 months (full metabolic panel, organ function, inflammatory markers, cancer surveillance)
• Synergy: MANDATORY - High-dose CD38 inhibitors (Quercetin 1000-1500 mg + Apigenin 100-150 mg); Resveratrol 500 mg or Pterostilbene 200 mg; consider TMG 1-2 g/day (methylation support)
• Caution: HIGH - Age-related polypharmacy (drug interaction risk); reduced organ function (clearance issues); cancer risk unknown
• Note: Parenteral routes (SubQ/IM/IV) may be necessary if oral precursors fail to restore NAD+ levels; consider physician supervision

Age-Based Dose Titration Strategy

Starting Protocol (All Ages):

1. Begin at 50% of target dose for age bracket
2. Increase by 25% every 2 weeks if well-tolerated
3. Monitor subjective response (energy, sleep, cognition, exercise recovery)
4. Obtain baseline and 8-week NAD+ levels if available
5. Target dose = dose that produces subjective benefit + NAD+ elevation ≥30%

Response Assessment (8-12 weeks):

• Excellent response: Subjective improvement + NAD+ ↑40-100% → maintain dose
• Moderate response: Modest improvement + NAD+ ↑20-40% → increase dose 25-50%
• Poor response: Minimal improvement + NAD+ ↑<20% → consider route change (oral → SubQ) or add CD38 inhibitors
• No response: No improvement + NAD+ unchanged → investigate:
  • Poor absorption (GI issues, age-related decline)
  • High CD38 activity (chronic inflammation)
  • NAMPT polymorphisms (genetic limitation)
  • Product quality issues (degraded NMN, inactive formulation)

Sex-Specific Dosing Considerations

NAD+ metabolism exhibits sex differences due to hormonal influences, body composition, and enzyme expression patterns.

Male vs Female NAD+ Physiology

Male-Specific Dosing

Premenopausal Males (Age 20-40):

• Baseline: Higher testosterone → better mitochondrial function → lower supplementation need
• Dose: Standard age-bracket dosing (see above)
• Focus: Performance enhancement, recovery optimization
• Synergy: Creatine (ATP/NAD+ synergy), CoQ10 (mitochondrial support)

Andropausal Males (Age 40-60):

• Issue: Testosterone decline → mitochondrial dysfunction → NAD+ demand increases
• Dose: +20-30% above standard for age bracket
  • Example: Age 50 → 1200-1500 mg NR/day instead of 1000 mg
• Focus: Metabolic health, muscle preservation, libido, cognitive function
• Synergy: If on TRT → NAD+ synergizes with testosterone for mitochondrial biogenesis
  • Combination: NR 1000 mg + Testosterone optimization → enhanced muscle NAD+ utilization
• Monitoring: SHBG (affects testosterone bioavailability, correlates with NAD+ status), HbA1c, hs-CRP

Older Males (Age 60+):

• Issue: Severe androgen decline + NAD+ depletion → metabolic crisis
• Dose: +30-40% above standard for age bracket (males have higher lean mass NAD+ demand)
  • Example: Age 70 → SubQ 600-700 mg 6x/week instead of 500 mg
• Focus: Frailty prevention, sarcopenia reversal, cognitive preservation
• Synergy: TRT + NAD+ + resistance training = powerful muscle preservation triad
• Caution: Prostate health monitoring (PSA, DRE); NAD+ effects on prostate unclear

Female-Specific Dosing

Premenopausal Females (Age 20-40):

• Baseline: Estrogen ↑ NAMPT activity → endogenous NAD+ synthesis higher
• Dose: -10-20% below standard for age bracket (estrogen provides NAD+ support)
  • Example: Age 35 → 200-250 mg NR/day instead of 300 mg
• Cycle Considerations:
  • Follicular phase (Days 1-14): Higher estrogen → lower NAD+ supplement need
  • Luteal phase (Days 15-28): Progesterone dominance, estrogen drop → increase dose 20-30%
  • Some women cycle NMN/NR dosing with menstrual cycle
• Focus: Energy, mood stability (NAD+ affects serotonin synthesis), PMS symptom reduction
• Synergy: Magnesium (PMS, mitochondrial cofactor), B-vitamins (methylation support)

Perimenopausal Females (Age 40-55):

• Issue: Erratic estrogen → NAMPT activity fluctuates → NAD+ instability
• Dose: Standard for age bracket with flexibility for symptom-based adjustment
  • Example: Age 48 → 500-750 mg NR/day, adjust based on hot flashes, fatigue, brain fog
• Symptom-Based Titration:
  • Increase dose during symptomatic phases (estrogen nadirs)
  • May need +50% dose during severe hot flash episodes (acute NAD+ depletion)
• Focus: Hot flash reduction (NAD+ stabilizes hypothalamic thermoregulation), mood, sleep, metabolic health
• Synergy: Black cohosh, evening primrose oil (symptom management); NAD+ addresses root mitochondrial dysfunction
• Note: HRT (estrogen therapy) reduces NAD+ supplementation need by ~20-30% (restores NAMPT activity)

Postmenopausal Females (Age 55+):

• Issue: Estrogen collapse → NAMPT activity plummets → Steeper NAD+ decline than males
• Dose: +30-50% above standard for age bracket (compensate for estrogen loss)
  • Example: Age 60 → 1800-2000 mg NR/day OR SubQ 400-500 mg 6x/week (vs male 350-400 mg)
• Critical Window: First 5 years post-menopause show steepest NAD+ decline; aggressive repletion warranted
• Focus: Bone health (NAD+ affects osteoblast function), cardiovascular protection, cognitive preservation, metabolic health
• Synergy: MANDATORY CD38 inhibitors (Quercetin 1000 mg)—CD38 expression surges post-menopause
• HRT Interaction: If on HRT (estrogen/progesterone):
  • Estradiol ↑ NAMPT → reduce NAD+ dose by 20-30%
  • Progesterone neutral to NAD+ metabolism
  • SERM (tamoxifen, raloxifene) effects unclear; monitor response
• Monitoring: Bone density (DEXA), cardiovascular markers (ApoB, Lp(a), hs-CRP), cognitive testing

Pregnant/Lactating Females:

• Recommendation: AVOID NAD+ supplementation
• Rationale: No safety data; theoretical risks (rapid cell division, fetal development)
• Exception: Prenatal vitamins contain niacin (NAM); this is adequate

Hormonal Therapy Interactions

Males on TRT (Testosterone Replacement):

• Effect: TRT ↑ mitochondrial biogenesis → ↑ NAD+ utilization → may require higher NAD+ doses
• Recommendation: Standard male dosing + 20-30% if on TRT
• Synergy: Powerful combination—testosterone drives muscle growth, NAD+ provides mitochondrial energy capacity
• Monitoring: Hematocrit (both TRT and NAD+ may increase RBC production)

Females on HRT (Estrogen ± Progesterone):

• Effect: Estrogen ↑ NAMPT → ↓ NAD+ supplementation need by 20-30%
• Recommendation: Reduce standard female dosing by 20-30% if on HRT
• Note: Bioidentical vs synthetic estrogen effects likely similar (both activate estrogen receptors → NAMPT)

Thyroid Hormone (T3/T4):

• Effect: Thyroid hormone ↑ metabolic rate → ↑ NAD+ consumption → may require higher doses
• Recommendation: +10-20% dose if on thyroid replacement (especially T3)
• Monitoring: Ensure thyroid levels optimized before attributing symptoms to NAD+ deficiency

DHEA Supplementation:

• Effect: DHEA → androgen/estrogen conversion → sex-specific NAD+ effects
• Recommendation: Treat as mild HRT; adjust NAD+ dose accordingly (reduce 10-15% in females on DHEA)

Goal Archetype Integration: NAD+ for Specific Outcomes

NAD+ is a foundational metabolic cofactor relevant to ALL optimization goals. However, dosing, timing, and synergistic protocols differ by primary objective.

Goal 1: Longevity & Healthspan Extension

Primary Mechanisms:

• SIRT1 activation → PGC-1α → mitochondrial biogenesis → cellular energy restoration
• SIRT6 activation → genomic stability → reduced DNA damage accumulation
• Enhanced mitophagy → removal of dysfunctional mitochondria
• Reduced chronic inflammation (via improved mitochondrial ROS management)
• Stem cell function preservation

Dosing Strategy:

• Oral NR: 500-1000 mg/day (chronic, indefinite)
• Oral NMN: 300-500 mg/day
• SubQ NAD+ (alternative): 250-300 mg 3-4x/week
• Rationale: Steady-state NAD+ elevation; long-term sirtuin activation
• Age Consideration: Start in 40s for maximum benefit; aggressive dosing 50+

Timing:

• Morning dose preferred (aligns with circadian NAD+ rhythms; supports daytime energy metabolism)
• Fasting state ideal (mimics caloric restriction; enhances AMPK/SIRT1 activation)

Synergistic Compounds:

• Resveratrol 250-500 mg/day (SIRT1 activator; synergistic with NAD+)
• Pterostilbene 150-200 mg/day (better bioavailability than resveratrol)
• Quercetin 500-1000 mg/day (CD38 inhibitor; preserves NAD+ from degradation)
• Apigenin 50-100 mg/day (CD38 inhibitor; anti-inflammatory)
• Metformin 500-1000 mg/day (if tolerated; AMPK activator, synergizes with NAD+)
• Rapamycin (off-label): 5-6 mg weekly (mTOR inhibition + NAD+ = powerful longevity stack; requires physician)

Lifestyle Synergies:

• Caloric restriction (10-20%): ↑ NAD+/NADH ratio endogenously
• Time-restricted eating (16:8): Supports circadian NAD+ oscillations
• Exercise (Zone 2 cardio): ↑ mitochondrial demand → ↑ NAD+ utilization efficiency
• Sauna/heat stress: ↑ heat shock proteins → mitochondrial protection (NAD+-independent but complementary)

Monitoring:

• Baseline (Age 40): NAD+ levels, VO2 max, HbA1c, hs-CRP, ApoB, Lp(a), DEXA scan
• Annual: Repeat above; add cognitive testing (MoCA), grip strength, gait speed
• Goal Metrics:
  • NAD+ levels ≥80% of age-20 baseline (if measurable)
  • hs-CRP <0.5 mg/L
  • HbA1c <5.3%
  • VO2 max maintained or improved
  • No decline in muscle mass (DEXA)

Evidence Level: ⭐⭐⭐☆☆ (3/5)

• Strong preclinical data (lifespan extension in mice)
• Human data shows NAD+ elevation and some biomarker improvements
• No long-term RCT proving lifespan extension in humans (yet)

Goal 2: Cognitive Optimization & Neuroprotection

Primary Mechanisms:

• Neuronal NAD+ restoration → improved ATP production → enhanced synaptic function
• SIRT1 in neurons → BDNF ↑ → neuroplasticity
• Reduced neuroinflammation (microglial NAD+ metabolism)
• Enhanced axonal myelination (oligodendrocyte NAD+ dependency)
• Protection against excitotoxicity (NAD+ as neuroprotectant)

Dosing Strategy:

• Sublingual NMN: 300-500 mg/day (better CNS penetration—theoretical)
• Intranasal NAD+: 50-100 mg/day (direct olfactory → CNS delivery)
• Oral NR: 500-1000 mg/day (systemic approach)
• IV NAD+ (acute cognitive boost): 500 mg biweekly (anecdotal benefits for brain fog)

Timing:

• Morning dose (cognitive peak 2-4 hours post-administration)
• Pre-cognitively demanding task (acute cognitive enhancement)

Synergistic Compounds:

• Lion's Mane 1-3 g/day (NGF ↑; synergizes with NAD+ for neuroplasticity)
• Alpha-GPC 300-600 mg (cholinergic support)
• Omega-3 (DHA) 1-2 g/day (membrane fluidity; mitochondrial function)
• Methylene Blue 0.5-1 mg/kg (mitochondrial ETC enhancer; USE CAUTIOUSLY)
• Cerebrolysin (peptide): 5-10 mL IM (if accessible; neuroprotection)

Lifestyle Synergies:

• Aerobic exercise (Zone 2): ↑ BDNF, ↑ cerebral blood flow
• Cognitive training: NAD+ supports neuroplasticity needed for learning
• Sleep optimization: NAD+ improves sleep quality (circadian regulation)

Monitoring:

• Subjective: Focus, memory, processing speed, brain fog
• Objective: Cognitive testing (MoCA, Stroop test, digit span)
• Advanced: fMRI (research setting); NAD+ levels in CSF (not clinically available)

Evidence Level: ⭐⭐☆☆☆ (2/5)

• Preclinical data strong (neuroprotection in AD/PD models)
• Human data very limited (mostly anecdotal from IV NAD+ clinics)
• Sublingual/intranasal NAD+ CNS penetration not clinically validated

Goal 3: Fat Loss & Metabolic Optimization

Primary Mechanisms:

• ↑ NAD+ → ↑ SIRT1 → ↑ PGC-1α → mitochondrial biogenesis in adipose tissue
• Enhanced lipolysis (NAD+-dependent enzymes in fat breakdown)
• Improved insulin sensitivity (Yoshino 2021: 25% ↑ in muscle glucose uptake)
• ↑ Energy expenditure (brown adipose tissue activation)
• Reduced hepatic steatosis (liver NAD+ restores fat oxidation)

Dosing Strategy:

• NMN (preferred): 300-500 mg/day (best evidence for insulin sensitivity)
  • Yoshino 2021 used 250 mg/day; clinical benefit proven
• NR (alternative): 500-1000 mg/day
• Timing: MORNING, FASTED STATE (enhances fat oxidation; mimics caloric restriction)

Synergistic Compounds:

• Berberine 500 mg 2-3x/day (AMPK activator; glucose disposal; synergizes with NAD+)
• Metformin 500-1000 mg/day (if prescribed; AMPK activation)
• GLP-1 agonist (semaglutide/tirzepatide): POWERFUL combination
  • GLP-1 → ↓ appetite, ↓ caloric intake
  • NAD+ → preserves muscle, maintains metabolic rate, prevents metabolic adaptation
  • CRITICAL: NAD+ prevents muscle loss during GLP-1-induced weight loss
• Caffeine 200-400 mg (lipolysis; NAD+ enhances mitochondrial fat oxidation capacity)

Lifestyle Synergies:

• Caloric deficit (15-25%): Required for fat loss; NAD+ preserves metabolic rate
• High protein (1.6-2.2 g/kg): Muscle preservation during deficit
• Resistance training: NAD+ supports muscle NAD+ pools → maintains strength during cut
• HIIT or Zone 2 cardio: NAD+ enhances fat oxidation capacity
• Sleep (7-9 hr): NAD+ improves sleep; poor sleep → insulin resistance

Monitoring:

• Weekly: Body weight, waist circumference
• Monthly: DEXA scan (track fat mass vs lean mass)
• Every 3 months: Fasting insulin, HbA1c, liver enzymes (AST, ALT), lipid panel
• Goal Metrics:
  • Fat loss 0.5-1% body weight/week
  • Lean mass maintained or increased (NAD+ + protein + resistance training)
  • Fasting insulin <5 μIU/mL
  • HOMA-IR <1.0

Evidence Level: ⭐⭐⭐⭐☆ (4/5)

• Strong human evidence: Yoshino 2021 (NMN improved insulin sensitivity 25%)
• Preclinical data robust (fat loss, metabolic improvements)
• Real-world use common; anecdotal success high

Critical Insight for Fat Loss: NAD+ is NOT a fat burner (does not directly cause fat loss). It is a metabolic optimizer that:

1. Improves insulin sensitivity → better nutrient partitioning
2. Preserves muscle during caloric deficit → maintains metabolic rate
3. Enhances mitochondrial fat oxidation → uses fat for fuel more efficiently
4. Prevents metabolic adaptation → sustains weight loss

Use Case: Best for individuals in caloric deficit (especially on GLP-1) to prevent muscle loss and metabolic slowdown.

Goal 4: Muscle Building & Anabolism

Primary Mechanisms:

• Mitochondrial biogenesis in muscle → ↑ ATP production → training capacity
• Enhanced muscle protein synthesis (NAD+ required for ribosomal function)
• Improved exercise-induced AMPK/SIRT1 signaling → adaptive response
• Reduced muscle inflammation → faster recovery
• Satellite cell activation (muscle stem cells; NAD+-dependent)

Dosing Strategy:

• NMN (preferred): 500-750 mg/day (muscle-targeted effects)
• NR (alternative): 1000 mg/day
• SubQ NAD+ (advanced): 300-400 mg post-workout 3-4x/week
• Timing: POST-WORKOUT (enhances recovery, muscle glycogen replenishment, mitochondrial adaptation)

Synergistic Compounds:

• Creatine 5 g/day (ATP/phosphocreatine system; synergizes with NAD+ for energy production)
• HMB 3 g/day (anti-catabolic; preserves muscle during hard training)
• BPC-157 250-500 mcg/day SubQ (tissue repair; angiogenesis; recovery)
• TB-500 2-5 mg/week SubQ (muscle repair, inflammation modulation)
• Testosterone (if on TRT): Powerful synergy—test drives growth, NAD+ provides energy
• IGF-1 LR3 or CJC/Ipamorelin (GH peptides): Anabolic signaling + NAD+ mitochondrial support = potent combination

Lifestyle Synergies:

• Caloric surplus (10-20%): Required for muscle gain
• High protein (1.6-2.2 g/kg): Substrate for muscle protein synthesis
• Progressive overload training: NAD+ supports training capacity and recovery
• Sleep (8-9 hr): NAD+ + GH release during sleep = maximal recovery

Monitoring:

• Monthly: DEXA scan (lean mass gain), strength metrics (1RM on key lifts)
• Every 3 months: Testosterone (free/total), IGF-1, hs-CRP (overtraining marker)
• Goal Metrics:
  • Lean mass gain 0.5-1 kg/month (beginners 1-2 kg)
  • Strength progression 2.5-5% monthly on compound lifts
  • Recovery (subjective): reduced DOMS, improved workout frequency tolerance

Evidence Level: ⭐⭐☆☆☆ (2/5)

• Preclinical data: NAD+ improves exercise capacity, mitochondrial biogenesis
• Human data: Limited RCTs; some show improved exercise performance (Liao 2021: 6-minute walk test)
• Anabolic effects indirect (via improved training capacity/recovery, not direct muscle protein synthesis)

Critical Insight for Muscle Building: NAD+ is NOT an anabolic agent (does not directly build muscle like testosterone, IGF-1). It is a training enhancer that:

1. Increases training capacity → more volume → more growth stimulus
2. Improves recovery → higher training frequency → more growth
3. Enhances mitochondrial adaptation → better nutrient utilization

Use Case: Best for athletes/bodybuilders seeking improved work capacity and recovery, especially when stacking with anabolic compounds.

Goal 5: Recovery & Healing (Injury, Surgery, Illness)

Primary Mechanisms:

• DNA repair (PARP activation requires NAD+; replenishing NAD+ supports repair)
• Tissue regeneration (stem cell NAD+ dependency)
• Reduced inflammation (improved mitochondrial function → less ROS → less inflammatory signaling)
• Angiogenesis (new blood vessel formation; NAD+-dependent)
• Collagen synthesis (fibroblast NAD+ metabolism)

Dosing Strategy:

• Acute Phase (0-2 weeks post-injury/surgery):
  • IV NAD+ (if accessible): 750-1000 mg every 2-3 days (rapid tissue NAD+ repletion)
  • SubQ NAD+ (alternative): 400-500 mg daily
  • Oral NMN: 750-1000 mg/day (divided doses)
• Subacute Phase (2-8 weeks):
  • SubQ NAD+: 300-400 mg 4-5x/week
  • Oral NMN/NR: 500-750 mg/day
• Recovery Phase (8+ weeks):
  • Transition to maintenance dosing for age (see above)

Timing:

• Multiple daily doses (maintain steady NAD+ levels for continuous repair)

Synergistic Compounds:

• BPC-157 250-500 mcg SubQ daily (POWERFUL tissue repair peptide; angiogenesis, collagen synthesis)
• TB-500 5-10 mg SubQ 2x/week (systemic healing, anti-inflammatory)
• GHK-Cu 1-3 mg SubQ daily (collagen remodeling, anti-inflammatory, copper peptide)
• Thymosin Beta-4 (TB-4, parent of TB-500): Similar to TB-500
• Collagen peptides 10-20 g/day oral (substrate for tissue repair)
• Vitamin C 1-2 g/day (collagen synthesis cofactor)
• Zinc 30-50 mg/day (wound healing, immune function)

Lifestyle Synergies:

• Sleep (9+ hr if possible): Healing occurs during sleep; GH release maximal
• Protein (2-2.5 g/kg): High protein needs during recovery
• Caloric adequacy: Do NOT calorie restrict during healing (impairs recovery)
• Light movement: Promotes blood flow, nutrient delivery (avoid immobilization)

Monitoring:

• Subjective: Pain levels, range of motion, functional capacity
• Objective: Imaging (MRI, ultrasound) for structural healing
• Labs: hs-CRP (inflammation), albumin (nutritional status), complete blood count

Evidence Level: ⭐⭐☆☆☆ (2/5)

• Preclinical data: NAD+ supports tissue repair, regeneration
• Human data: Very limited; mostly extrapolated from IV NAD+ clinic anecdotes
• BPC-157 has stronger direct evidence for tissue healing than NAD+ (but they synergize)

Critical Insight for Recovery: NAD+ provides the cellular energy infrastructure for healing, but does not directly repair tissues. Think of it as "fuel for the repair machinery." Combine with direct tissue repair peptides (BPC-157, TB-500) for maximum effect.

Marker-Based Dosing Algorithms

Optimal NAD+ dosing is informed by biomarkers that reflect NAD+ status, metabolic health, and inflammatory state.

Tier 1: Direct NAD+ Assessment (If Available)

Blood NAD+ Levels:

• Test: Whole blood or PBMC (peripheral blood mononuclear cell) NAD+ concentration
• Cost: $200-$500 (not widely available; specialty labs)
• Interpretation:
  • Optimal: ≥80% of age-20 baseline (if historical data available)
  • Adequate: 60-80% of age-20 baseline
  • Depleted: 40-60% of age-20 baseline → increase dose 50%
  • Severely Depleted: <40% of age-20 baseline → double dose or switch to parenteral route

Limitation: No standardized reference ranges; high inter-individual variability; PBMC NAD+ may not reflect tissue NAD+.

Dosing Adjustment:

• Measure baseline, then 8-12 weeks post-supplementation
• Goal: ≥30% increase from baseline; ideally ≥50%
• If <30% increase → escalate dose or add CD38 inhibitors

Tier 2: Indirect NAD+ Markers (Widely Available)

HbA1c (Glycated Hemoglobin):

• Rationale: NAD+ improves insulin sensitivity → better glucose control
• Target:
  • Optimal: <5.3%
  • Good: 5.3-5.6%
  • Prediabetic: 5.7-6.4% → INCREASE NAD+ DOSE; use NMN (proven benefit)
  • Diabetic: ≥6.5% → aggressive NAD+ dosing + medical management
• Dosing Adjustment:
  • HbA1c 5.7-6.4%: Use NMN 500-750 mg/day (Yoshino 2021 protocol)
  • HbA1c ≥6.5%: NMN 750-1000 mg/day OR SubQ NAD+ 300-400 mg 5x/week

Fasting Insulin:

• Rationale: Hyperinsulinemia indicates insulin resistance; NAD+ improves sensitivity
• Target:
  • Optimal: <5 μIU/mL
  • Acceptable: 5-10 μIU/mL
  • Insulin Resistant: >10 μIU/mL → INCREASE NAD+ DOSE
  • Severe IR: >15 μIU/mL → aggressive NAD+ + berberine/metformin
• Dosing Adjustment:
  • Insulin 10-15: NMN 500 mg/day
  • Insulin >15: NMN 750-1000 mg/day + berberine 500 mg 3x/day

hs-CRP (High-Sensitivity C-Reactive Protein):

• Rationale: Chronic inflammation ↑ CD38 expression → ↑ NAD+ degradation
• Target:
  • Optimal: <0.5 mg/L
  • Low Risk: 0.5-1.0 mg/L
  • Moderate Risk: 1.0-3.0 mg/L → ADD CD38 INHIBITORS (Quercetin 500-1000 mg)
  • High Risk: >3.0 mg/L → aggressive anti-inflammatory protocol + CD38 inhibitors + high-dose NAD+
• Dosing Adjustment:
  • hs-CRP 1-3 mg/L: Standard NAD+ dose + Quercetin 500-1000 mg
  • hs-CRP >3 mg/L: High-dose NAD+ + Quercetin 1000-1500 mg + Apigenin 100 mg

Liver Enzymes (AST, ALT):

• Rationale: NAD+ supports hepatic fat oxidation; elevated enzymes may indicate fatty liver (NAD+ depletion state)
• Target:
  • Optimal: AST <25, ALT <30 U/L
  • Acceptable: AST 25-35, ALT 30-40 U/L
  • Elevated: AST/ALT >40 U/L → possible NAFLD; NAD+ may help but investigate further
• Dosing Adjustment:
  • Elevated liver enzymes + metabolic syndrome: NMN 500-750 mg/day (hepatic NAD+ repletion may reduce steatosis)
• Caution: Very high liver enzymes (>3x upper limit) → rule out other liver disease before high-dose NAD+

SHBG (Sex Hormone-Binding Globulin):

• Rationale: SHBG correlates with metabolic health; low SHBG indicates insulin resistance
• Target (Males):
  • Optimal: 30-50 nmol/L
  • Low: <20 nmol/L → insulin resistance, metabolic syndrome → INCREASE NAD+
• Target (Females, premenopausal):
  • Optimal: 40-120 nmol/L
  • Low: <30 nmol/L → PCOS, insulin resistance → NMN beneficial
• Dosing Adjustment:
  • SHBG <20 (males) or <30 (females): NMN 500-750 mg/day + metabolic optimization

Tier 3: Functional/Subjective Markers

Energy & Fatigue:

• Assessment: Subjective energy scale (1-10); daily tracking
• Dosing Adjustment:
  • Persistent fatigue despite adequate sleep → increase NAD+ dose 25-50%
  • No improvement after 8 weeks → consider alternative diagnosis (thyroid, anemia, depression)

Exercise Capacity:

• Assessment: VO2 max (gold standard), 6-minute walk test, or subjective exercise tolerance
• Dosing Adjustment:
  • Declining exercise capacity with age → NAD+ repletion may restore (Liao 2021 data)
  • No improvement after 12 weeks → NAD+ may not be limiting factor

Cognitive Function:

• Assessment: Subjective (brain fog, focus, memory) or objective (MoCA, digit span)
• Dosing Adjustment:
  • Brain fog, poor focus → trial NAD+ 500-1000 mg/day for 8 weeks
  • Consider sublingual/intranasal for CNS-targeted delivery

Integrated Dosing Algorithm

Step 1: Establish Baseline

• Age, sex, body composition, medical history
• Labs: HbA1c, fasting insulin, hs-CRP, liver enzymes, SHBG
• Optional: Blood NAD+ levels

Step 2: Assign Starting Dose

• Use age-stratified dosing (see above)
• Adjust for sex (females +30-50% post-menopause; -10-20% premenopausal)
• Adjust for inflammation (hs-CRP >1 → add CD38 inhibitors)
• Adjust for metabolic dysfunction (HbA1c >5.7 or insulin >10 → use NMN, higher dose)

Step 3: Titrate Based on Response

• Assess at 8-12 weeks:
  • Subjective: Energy, cognition, exercise tolerance
  • Objective: Repeat labs (HbA1c, hs-CRP, liver enzymes)
  • Optimal: NAD+ levels (if available)
• Good response: Maintain dose
• Partial response: Increase dose 25-50%
• No response: Investigate:
  • Switch route (oral → SubQ)
  • Add CD38 inhibitors (Quercetin 1000 mg)
  • Check product quality (NMN degradation common)
  • Consider genetic factors (NAMPT polymorphisms)

Step 4: Long-Term Optimization

• Reassess every 6-12 months
• Adjust dose as age, metabolic state, or goals change
• Monitor for long-term safety (cancer surveillance, liver/kidney function)

Combination Strategies

NR + CD38 Inhibitors:

• Quercetin (500-1000 mg/day) or Apigenin (50-100 mg/day) to reduce NAD+ degradation
• Theoretical synergy; limited human data

NR + Resveratrol:

• Resveratrol activates SIRT1; may synergize with NAD+ boosting
• Typical: NR 500 mg + Resveratrol 250-500 mg daily
• Some commercial formulations combine both

NR + Pterostilbene:

• Pterostilbene (methylated resveratrol analog) with better bioavailability
• Marketed together in longevity supplement blends

NMN + Berberine (Metabolic Optimization):

• Berberine 500 mg 3x/day (AMPK activator, glucose disposal agent)
• NMN 500 mg/day (insulin sensitivity)
• Powerful combination for prediabetes, metabolic syndrome

NAD+ + GLP-1 Agonist (Fat Loss with Muscle Preservation):

• Semaglutide 1-2.4 mg weekly OR Tirzepatide 5-15 mg weekly
• NMN 500-750 mg/day OR SubQ NAD+ 300-400 mg 4x/week
• CRITICAL combination: GLP-1 drives weight loss; NAD+ preserves muscle mass and metabolic rate

NAD+ + TRT (Males, Anabolic Stack):

• Testosterone cypionate/enanthate 100-200 mg/week
• NR/NMN 1000 mg/day OR SubQ NAD+ 300-400 mg 3-4x/week
• Synergy: Testosterone drives anabolism; NAD+ provides mitochondrial support for growth

NAD+ + BPC-157/TB-500 (Recovery Stack):

• BPC-157 250-500 mcg SubQ daily
• TB-500 5 mg SubQ 2x/week
• NAD+ (SubQ 400-500 mg 4-5x/week OR oral 750-1000 mg/day)
• Synergy: Peptides drive tissue repair; NAD+ provides cellular energy for healing

Special Populations

Older Adults (>60 years):

• Greatest benefit expected due to age-related NAD+ decline
• Start with lower doses (NR 250 mg or NMN 125 mg) and titrate

Prediabetes / Metabolic Syndrome:

• NMN 250 mg/day shown to improve insulin sensitivity in prediabetic women
• Potential adjunct to lifestyle interventions

Athletes:

• Some use NR/NMN for enhanced exercise capacity and recovery
• Evidence mixed; not prohibited by WADA

Contraindications (Theoretical):

• Active cancer (NAD+ supports rapidly dividing cells)
• Severe liver disease (altered metabolism)

Monitoring

No Routine Monitoring Required:

• NAD+ precursors generally safe; routine labs unnecessary

Optional (For Optimization):

• NAD+ Blood Levels: Specialized test (~$200-$500); demonstrates response
• Metabolic Markers: Fasting glucose, insulin, HbA1c (if using for metabolic health)

References:

• What is really known about NR supplementation - Science Advances
• NAD+ Precursors NMN and NR: Dietary Contribution - PMC
• Dietary Supplementation With NAD+-Boosting Compounds - PMC

Clinical Research & Evidence

Preclinical Studies (Rodents)

Lifespan Extension:

• NR supplementation: 10-15% increase in median lifespan in aged mice
• NMN treatment: Delayed age-associated physiological decline; improved muscle function, bone density, insulin sensitivity
• Mechanism: SIRT1 activation, mitochondrial biogenesis, reduced inflammation

Mitochondrial Function:

• NAD+ repletion reversed age-related mitochondrial dysfunction
• Improved oxidative phosphorylation, reduced ROS production
• Enhanced mitophagy (removal of damaged mitochondria)

Stem Cell Rejuvenation:

• NR delayed senescence of neural and melanocyte stem cells
• Improved stem cell function and regenerative capacity

Neurodegeneration Models:

• NAD+ precursors showed neuroprotection in Alzheimer's and Parkinson's disease models
• Reduced neuroinflammation, enhanced synaptic plasticity

Human Clinical Trials

Nicotinamide Riboside (NR)

Study 1: Dose-Escalation Safety Trial (Dollerup et al., 2018 - PLOS One)

• Design: Open-label, dose-escalation (100, 300, 1000 mg NR single dose)
• Population: Healthy volunteers (n=12)
• Results:
  • NAD+ levels increased dose-dependently (22%, 51%, 142%)
  • Well-tolerated; no serious adverse events
  • Peak NAD+ at 8 hours post-dose

Study 2: Chronic NR in Older Adults (Martens et al., 2018 - Nature Communications)

• Design: Randomized, double-blind, placebo-controlled
• Population: Healthy middle-aged and older adults (n=24), 500-1000 mg/day for 6 weeks
• Results:
  • NAD+ levels increased ~60% in blood
  • No improvement in blood pressure, arterial stiffness, or insulin sensitivity
  • Well-tolerated
• Limitation: Short duration; healthy subjects may not show benefits

Study 3: NR in Heart Failure (Zhou et al., 2023)

• Design: Randomized trial, 1000 mg/day NR for 12 weeks
• Population: Heart failure patients (n=30)
• Results:
  • Increased NAD+ levels
  • No improvement in 6-minute walk distance, cardiac ejection fraction
• Conclusion: NAD+ boosting insufficient alone for clinical HF improvement

Systematic Review (2024):

• Analyzed 489 participants across multiple NR trials
• Findings:
  • Consistent NAD+ elevation (10-100%)
  • Inconsistent clinical benefits: Some trials showed improvements in insulin sensitivity, lipid profiles; others showed no effect
  • Generally well-tolerated
• Conclusion: "While NR raises NAD+, translation to meaningful health improvements in humans is not yet established"

Nicotinamide Mononucleotide (NMN)

Study 1: Single-Dose Safety (Irie et al., 2020 - PMC)

• Design: Single oral dose escalation (100, 250, 500 mg NMN)
• Population: Healthy volunteers (n=10)
• Results:
  • No significant adverse effects
  • Safe and well-tolerated

Study 2: NMN in Prediabetic Women (Yoshino et al., 2021 - Science)

• Design: Randomized, placebo-controlled, 250 mg/day NMN for 10 weeks
• Population: Postmenopausal women with prediabetes (n=25)
• Results:
  • Significantly increased NAD+ levels in PBMCs
  • Improved insulin sensitivity in skeletal muscle (~25% increase in insulin-stimulated glucose uptake)
  • Upregulated muscle insulin signaling and remodeling genes
• Significance: First human RCT showing metabolic benefit of NMN

Study 3: NMN in Middle-Aged Adults (Liao et al., 2021)

• Design: Randomized, 300 mg/day NMN for 60 days
• Population: Healthy middle-aged adults (n=66)
• Results:
  • Increased blood NAD+
  • Improved walking endurance (6-minute walk test)
  • No significant adverse effects

Intravenous NAD+ Studies

Study 1: PK Study (Grant et al., 2019)

• Design: 750 mg NAD+ IV over 6 hours
• Population: Healthy volunteers (n=11)
• Results:
  • Well-tolerated; no adverse events
  • Stable liver and kidney function
• Limitation: Single infusion; no long-term data

Study 2: IV NAD+ vs. NR IV (Airhart et al., 2024 - medRxiv preprint)

• Design: Randomized, placebo-controlled pilot comparing NAD+ IV vs. Niagen+ (NR) IV
• Results:
  • NR IV had fewer and less severe adverse effects than NAD+ IV
  • NAD+ IV required slower infusion (mean tolerable infusion time 75% longer than NR IV)
  • Both raised blood NAD+ levels

Evidence Gaps

NO Long-Term RCTs (>1 Year):

• Unknown whether chronic NAD+ boosting extends healthspan or lifespan in humans
• Unknown long-term safety

NO Phase 3 Trials:

• No large-scale (n>500) trials for any indication
• FDA approval for specific diseases not pursued

Inconsistent Endpoints:

• Trials measure different outcomes (metabolic markers, physical function, cognition)
• Lack of standardized primary endpoints

Healthy vs. Disease Populations:

• Most trials in healthy subjects show minimal clinical benefit
• Greater effects seen in metabolically compromised individuals (prediabetes, heart failure)

Cancer Risk Unknown:

• NAD+ supports cell proliferation; theoretical concern for promoting tumor growth
• NO long-term cancer surveillance data

Current Consensus

What We Know:

• NR and NMN safely raise blood NAD+ levels in humans
• Some metabolic benefits (insulin sensitivity) in at-risk populations
• Generally well-tolerated for ≤12 weeks

What We Don't Know:

• Whether NAD+ boosting extends lifespan or healthspan in humans
• Optimal dose and duration
• Long-term safety (>1 year)
• Cancer risk
• Which populations benefit most

References:

• What is really known about NR - Science Advances
• NAD+ Precursors NMN and NR - PMC
• Dietary Supplementation With NAD+-Boosting Compounds - PMC
• Oral NMN Safely Increases NAD+ - PMC

Safety Profile

NAD+ Precursors (NR, NMN) - Oral

Overall Safety:

• Generally well-tolerated in clinical trials up to 2000 mg/day (NR) and 500 mg/day (NMN)
• No serious adverse events reported in systematic reviews (489 participants across trials)

Common Side Effects (Mild, <10% incidence):

• Nausea
• Diarrhea or mild GI discomfort
• Headache
• Fatigue
• Skin flushing (rare with NR/NMN; common with nicotinic acid)

Rare Adverse Events:

• Calf cramps
• Rashes or erythema
• Abdominal discomfort

No Evidence Of:

• Hepatotoxicity (liver function tests normal in trials)
• Nephrotoxicity (renal function unaffected)
• Hematologic abnormalities
• Immunosuppression

Intravenous NAD+ Therapy

Infusion-Related Reactions (Common if Infused Too Rapidly):

• Nausea (most common; up to 50% if infused >200 mg/hr)
• Flushing and warmth
• Chest tightness or discomfort
• Palpitations
• Dizziness

Management:

• Slow infusion rate: 2-6 hours for 500-1000 mg dose
• Titrate: Start at 100-150 mg/hr; increase as tolerated
• Pre-medication: Some clinics use antihistamines or anti-nausea agents

Serious Adverse Events (Rare but Reported):

• Inflammatory Spike: hs-CRP elevation in up to 70% of patients receiving IV NAD+ (observed in case reports)
• Anaphylactoid Reactions: Rare; likely due to impurities or rapid administration
• Glucose Intolerance: Some reports of transient hyperglycemia
• Injection Site Infection: If aseptic technique not followed

Long-Term Safety Unknown:

• Most IV NAD+ therapy occurs in wellness clinics without systematic safety monitoring
• NO published data on repeated weekly infusions for >6 months
• Theoretical risks of chronic supraphysiological NAD+ levels

Theoretical Concerns

1. Cancer Risk

Concern:

• NAD+ supports cellular proliferation and DNA repair
• Cancer cells have high NAD+ demand; NAMPT overexpressed in many tumors
• Could NAD+ boosting "feed" cancer cells?

Counterarguments:

• Preclinical studies show reduced tumor incidence with NAD+ repletion in aged mice
• Sirtuins (activated by NAD+) have tumor-suppressive effects (via p53 regulation)
• Some oncologists theorize optimal NAD+ may prevent mutagenesis

Current Status:

• UNRESOLVED
• Prudent to avoid NAD+ boosting in active cancer until more data available
• Cancer surveillance recommended for long-term users

2. Sirtuin Overactivation

Concern:

• Chronic SIRT1 activation could have unintended metabolic effects

Evidence:

• NO adverse effects observed in trials with elevated sirtuin activity
• Caloric restriction (which activates sirtuins) has demonstrated safety in humans

3. Methylation Imbalance

Concern:

• NAM is methylated by NNMT enzyme to produce N-methyl-nicotinamide (excreted)
• High NAM levels (from NAD+ degradation) could deplete methyl donors (SAMe)

Evidence:

• Theoretical; no clinical evidence of methylation deficiency in NAD+ precursor users
• Could be mitigated by ensuring adequate B vitamin intake (folate, B12, B6)

Contraindications (Theoretical)

Absolute:

• Active malignancy (until cancer risk data clarified)
• Known hypersensitivity to niacin or derivatives

Relative:

• Pregnancy and lactation (no safety data)
• Severe hepatic impairment (altered NAD+ metabolism)
• Severe renal impairment (reduced excretion of metabolites)

Comprehensive Drug Interactions

CRITICAL LIMITATION: No systematic drug interaction studies exist for NAD+ precursors (NR, NMN) or IV NAD+ therapy. The following are theoretical interactions based on mechanistic understanding, case reports, and extrapolation from niacin (nicotinic acid) data.

General Principles:

1. NAD+ affects mitochondrial function, redox status, and energy metabolism—broad systemic effects
2. Drug interactions most likely via:
   • Metabolic interference (altered drug metabolism, mitochondrial effects)
   • Additive/synergistic effects (both drug and NAD+ affect same pathway)
   • Methylation competition (NAM methylation may deplete SAMe)
3. IV NAD+ has highest interaction risk (supraphysiological doses, rapid tissue exposure)
4. Oral NR/NMN at physiological doses likely low risk but monitor

Cardiovascular Medications

Statins (Atorvastatin, Rosuvastatin, Simvastatin, etc.):

• Interaction Mechanism:
  • Nicotinic acid (niacin) at HIGH doses (1000-3000 mg) potentiates statin-induced myopathy (muscle breakdown)
  • Mitochondrial toxicity synergy (both statins and high-dose niacin can impair mitochondrial function)
• Risk with NR/NMN: LOW (doses 500-1000 mg << high-dose niacin; no myopathy reports)
• Risk with IV NAD+: MODERATE (theoretical; no clinical data)
• Management:
  • Monitor for muscle pain, weakness, or cramping
  • Check CPK (creatine phosphokinase) if symptoms develop
  • NAD+ may theoretically protect against statin myopathy (mitochondrial support) but data lacking
• Recommendation: SAFE with monitoring; report new muscle symptoms immediately

Blood Pressure Medications (ACE Inhibitors, ARBs, Beta-Blockers, Calcium Channel Blockers):

• Interaction Mechanism:
  • Nicotinic acid causes vasodilation (prostaglandin-mediated) → can potentiate hypotension
  • NR/NMN at therapeutic doses: minimal vasodilatory effect
• Risk with NR/NMN: VERY LOW (no vasodilation at typical doses)
• Risk with IV NAD+: LOW-MODERATE (flushing reported; may transiently lower BP)
• Management:
  • Monitor blood pressure, especially after first IV NAD+ infusion
  • Dizziness, lightheadedness → hold BP meds day of IV infusion
• Recommendation: SAFE; caution with IV NAD+ in patients on multiple BP meds

Anticoagulants (Warfarin, Rivaroxaban, Apixaban):

• Interaction Mechanism:
  • No known pharmacokinetic or pharmacodynamic interaction
  • Theoretical: NAD+ affects platelet function (unclear direction)
• Risk: VERY LOW
• Management:
  • Warfarin: Monitor INR as usual; no dose adjustment expected
  • DOACs: No specific monitoring
• Recommendation: SAFE; standard monitoring sufficient

Antiplatelet Agents (Aspirin, Clopidogrel, Ticagrelor):

• Interaction Mechanism: None known
• Risk: VERY LOW
• Recommendation: SAFE

Diuretics (Furosemide, Hydrochlorothiazide, Spironolactone):

• Interaction Mechanism:
  • Nicotinic acid can impair glucose tolerance → may counteract diuretic benefits in diabetes
  • NR/NMN improves insulin sensitivity → may benefit diabetic patients on diuretics
• Risk: VERY LOW (beneficial interaction likely)
• Recommendation: SAFE

Metabolic & Endocrine Medications

Metformin:

• Interaction Mechanism:
  • SYNERGISTIC effects (both activate AMPK, improve mitochondrial function, enhance insulin sensitivity)
  • Metformin inhibits Complex I (mild); NAD+ supports mitochondrial function → may mitigate metformin side effects
• Risk: NONE (beneficial interaction)
• Management:
  • Combining metformin + NMN showed additive benefits in preclinical studies
  • Consider using together for metabolic syndrome, prediabetes
• Recommendation: HIGHLY COMPATIBLE; synergistic combination

Insulin & GLP-1 Agonists (Semaglutide, Tirzepatide, Liraglutide):

• Interaction Mechanism:
  • NAD+ improves insulin sensitivity → may reduce insulin requirements
  • GLP-1 + NAD+ = powerful fat loss stack (GLP-1 drives appetite suppression, NAD+ preserves muscle)
• Risk: LOW; hypoglycemia possible if insulin dose not adjusted
• Management:
  • Monitor blood glucose closely when starting NAD+ in insulin-dependent diabetics
  • May need to reduce insulin dose by 10-20% as NAD+ improves sensitivity
  • GLP-1 + NMN: excellent combination for fat loss with muscle preservation
• Recommendation: SAFE with glucose monitoring; may improve glycemic control

Thyroid Hormone (Levothyroxine, Liothyronine/T3):

• Interaction Mechanism:
  • Thyroid hormone ↑ metabolic rate → ↑ NAD+ consumption
  • NAD+ supplementation may be especially beneficial in hypothyroid patients
• Risk: NONE
• Management:
  • Ensure thyroid levels optimized before NAD+ therapy (TSH, Free T4, Free T3)
  • NAD+ may enhance energy/metabolism in adequately replaced hypothyroid patients
• Recommendation: SAFE; beneficial interaction likely

SGLT2 Inhibitors (Empagliflozin, Dapagliflozin):

• Interaction Mechanism:
  • SGLT2 inhibitors increase urinary glucose excretion → improve insulin sensitivity
  • Synergy with NAD+ (both improve metabolic health)
• Risk: NONE
• Recommendation: SAFE; potentially synergistic

Psychiatric Medications

SSRIs/SNRIs (Sertraline, Escitalopram, Venlafaxine, Duloxetine):

• Interaction Mechanism:
  • NAD+ affects serotonin synthesis (NAD+ required for tryptophan → serotonin pathway)
  • Theoretical: NAD+ may enhance SSRI efficacy (improved serotonin production)
  • Nicotinic acid can cause flushing; may be mistaken for serotonin syndrome (not true interaction)
• Risk: VERY LOW
• Management:
  • No dose adjustments needed
  • If patient reports flushing on IV NAD+, distinguish from serotonin syndrome (true SS includes hyperthermia, rigidity, altered mental status)
• Recommendation: SAFE; may improve mood/energy in depressed patients on SSRIs

Benzodiazepines (Alprazolam, Lorazepam, Clonazepam):

• Interaction Mechanism:
  • No known interaction
  • NAD+ improves mitochondrial function → may reduce sedation/fatigue from benzos (theoretical)
• Risk: VERY LOW
• Recommendation: SAFE

Stimulants (Adderall, Ritalin, Modafinil):

• Interaction Mechanism:
  • Stimulants ↑ dopamine/norepinephrine → ↑ metabolic demand
  • NAD+ supports mitochondrial function → may enhance stimulant efficacy or reduce crash
  • Anecdotally, biohackers combine NAD+ with stimulants for cognitive enhancement
• Risk: LOW
• Management:
  • Monitor for overstimulation (rare)
  • May allow lower stimulant dose if NAD+ improves baseline energy
• Recommendation: SAFE; potentially beneficial

Lithium:

• Interaction Mechanism:
  • No known interaction
  • Lithium toxicity risk if dehydration (IV NAD+ infusions require hydration)
• Risk: LOW
• Management:
  • Ensure adequate hydration during IV NAD+ therapy
  • Monitor lithium levels as usual
• Recommendation: SAFE with hydration

Antipsychotics (Olanzapine, Quetiapine, Risperidone):

• Interaction Mechanism:
  • Antipsychotics often cause metabolic syndrome (weight gain, insulin resistance)
  • NAD+ may counteract metabolic side effects (improved insulin sensitivity)
• Risk: NONE
• Management:
  • NAD+ (especially NMN) may benefit patients with antipsychotic-induced metabolic syndrome
• Recommendation: SAFE; potentially beneficial for metabolic side effects

Pain & Inflammation Medications

NSAIDs (Ibuprofen, Naproxen, Celecoxib):

• Interaction Mechanism:
  • NSAIDs inhibit COX enzymes → affect prostaglandin synthesis
  • Nicotinic acid flushing is prostaglandin-mediated; aspirin (COX-1 inhibitor) can block flushing
  • NR/NMN unlikely to cause flushing (not prostaglandin-mediated at therapeutic doses)
• Risk: VERY LOW
• Management:
  • If IV NAD+ flushing occurs, pre-treatment with aspirin 325 mg may reduce (used clinically with niacin)
• Recommendation: SAFE

Corticosteroids (Prednisone, Dexamethasone):

• Interaction Mechanism:
  • Corticosteroids cause insulin resistance, muscle wasting, mitochondrial dysfunction
  • NAD+ may counteract some steroid side effects (mitochondrial support, insulin sensitivity)
• Risk: NONE
• Management:
  • NAD+ may be especially beneficial in patients on chronic corticosteroids
• Recommendation: SAFE; may mitigate steroid side effects

Opioids (Oxycodone, Hydrocodone, Morphine, Fentanyl):

• Interaction Mechanism:
  • No known pharmacological interaction
  • NAD+ has been used in addiction medicine (IV NAD+ for opioid detox—controversial, limited evidence)
• Risk: VERY LOW
• Management:
  • NAD+ does NOT reverse opioid effects (not an antagonist)
  • Use IV NAD+ for detox only under medical supervision
• Recommendation: SAFE; no interaction with pain management

Antibiotics & Antivirals

Fluoroquinolones (Ciprofloxacin, Levofloxacin):

• Interaction Mechanism:
  • Fluoroquinolones cause mitochondrial toxicity (tendon rupture, neuropathy)
  • NAD+ may protect against fluoroquinolone mitochondrial damage (theoretical)
• Risk: NONE
• Management:
  • Consider NAD+ supplementation during fluoroquinolone therapy (mitochondrial protection)
• Recommendation: SAFE; may be protective

Macrolides (Azithromycin, Clarithromycin):

• Interaction Mechanism: None known
• Risk: VERY LOW
• Recommendation: SAFE

Antivirals (Acyclovir, Valacyclovir, Antiretrovirals):

• Interaction Mechanism:
  • Some antiretrovirals (NRTIs like AZT, d4T) cause severe mitochondrial toxicity
  • NAD+ may mitigate NRTI-induced mitochondrial dysfunction
• Risk: NONE
• Management:
  • NAD+ (especially NMN/NR) may benefit HIV patients on antiretroviral therapy (mitochondrial protection)
• Recommendation: SAFE; potentially beneficial

Chemotherapy & Immunosuppressants

Chemotherapy (Cisplatin, Doxorubicin, 5-FU, Taxanes, etc.):

• Interaction Mechanism:
  • CRITICAL CONCERN: NAD+ supports DNA repair (PARP activation) and cellular proliferation
  • Theoretical Risk: NAD+ might support cancer cell survival during chemotherapy
  • Counterargument: NAD+ may protect healthy cells from chemo toxicity (e.g., cisplatin nephrotoxicity, doxorubicin cardiotoxicity)
• Risk: UNKNOWN (data insufficient)
• Management:
  • AVOID NAD+ supplementation during active chemotherapy (prudent until data available)
  • Exception: Discuss with oncologist; some integrative oncologists use NAD+ to reduce chemo side effects (e.g., neuropathy)
  • May consider NAD+ AFTER chemotherapy completion for recovery
• Recommendation: AVOID during active chemo; discuss with oncologist

Immunosuppressants (Tacrolimus, Cyclosporine, Mycophenolate, Azathioprine):

• Interaction Mechanism:
  • NAD+ affects immune cell function (CD38 expression, T cell metabolism)
  • Theoretical: NAD+ might interfere with immunosuppression (unclear direction)
• Risk: UNKNOWN
• Management:
  • Use with caution in transplant patients or autoimmune disease on immunosuppression
  • Monitor for rejection (transplant) or disease flare (autoimmune)
  • Consult transplant/rheumatology team
• Recommendation: CAUTION; specialist consultation required

Checkpoint Inhibitors (Pembrolizumab, Nivolumab, Ipilimumab):

• Interaction Mechanism:
  • Checkpoint inhibitors activate immune system against cancer
  • NAD+ affects T cell metabolism; unclear if synergistic or antagonistic
• Risk: UNKNOWN
• Management:
  • Discuss with oncologist; emerging data suggests NAD+ metabolism affects checkpoint inhibitor response
• Recommendation: DISCUSS WITH ONCOLOGIST

Other Peptides & Performance-Enhancing Compounds

Testosterone (TRT):

• Interaction Mechanism:
  • HIGHLY SYNERGISTIC (testosterone drives anabolism, NAD+ provides mitochondrial support)
  • Testosterone ↑ mitochondrial biogenesis → ↑ NAD+ utilization → may require higher NAD+ doses
• Risk: NONE (beneficial interaction)
• Management:
  • Males on TRT: increase NAD+ dose by 20-30% for optimal synergy
  • Monitor hematocrit (both can increase RBC production)
• Recommendation: HIGHLY COMPATIBLE; powerful anabolic + metabolic stack

Growth Hormone & GH Peptides (CJC-1295, Ipamorelin, Tesamorelin):

• Interaction Mechanism:
  • SYNERGISTIC (GH drives anabolism/lipolysis, NAD+ supports mitochondrial function)
  • GH ↑ lipolysis → ↑ fatty acid oxidation (NAD+-dependent)
• Risk: NONE
• Management:
  • Excellent combination for fat loss, muscle building, anti-aging
  • NAD+ timing: may enhance GH-induced fat oxidation if taken in fasted state
• Recommendation: HIGHLY COMPATIBLE

BPC-157, TB-500, GHK-Cu (Healing Peptides):

• Interaction Mechanism:
  • SYNERGISTIC (peptides drive tissue repair, NAD+ provides cellular energy for healing)
  • No pharmacological interference
• Risk: NONE
• Recommendation: HIGHLY COMPATIBLE; commonly stacked for injury recovery

Thymosin Alpha-1 (Immune Peptide):

• Interaction Mechanism:
  • Both support immune function (NAD+ via T cell metabolism, TA-1 via thymus signaling)
  • Likely synergistic
• Risk: NONE
• Recommendation: SAFE; may be synergistic

Melanotan II, PT-141 (Tanning/Libido Peptides):

• Interaction Mechanism: None known
• Risk: VERY LOW
• Recommendation: SAFE

Supplements

Resveratrol/Pterostilbene:

• Interaction Mechanism: SYNERGISTIC (both activate SIRT1; NAD+ is sirtuin substrate)
• Recommendation: HIGHLY COMPATIBLE; commonly combined for longevity

Quercetin/Apigenin (CD38 Inhibitors):

• Interaction Mechanism: SYNERGISTIC (inhibit NAD+ degradation via CD38)
• Recommendation: HIGHLY COMPATIBLE; should be combined, especially age 50+

Berberine:

• Interaction Mechanism: SYNERGISTIC (both activate AMPK, improve insulin sensitivity)
• Recommendation: HIGHLY COMPATIBLE; excellent combination for metabolic health

Alpha-Lipoic Acid (ALA):

• Interaction Mechanism:
  • Both support mitochondrial function (ALA is antioxidant/cofactor)
  • Synergistic for metabolic health
• Recommendation: COMPATIBLE

CoQ10/Ubiquinol:

• Interaction Mechanism:
  • Both support mitochondrial ETC function
  • CoQ10 accepts electrons from Complex I/II; NAD+ donates to Complex I
  • Synergistic for mitochondrial health
• Recommendation: HIGHLY COMPATIBLE

Curcumin:

• Interaction Mechanism:
  • Curcumin activates AMPK, anti-inflammatory
  • May synergize with NAD+ for metabolic/inflammatory conditions
• Recommendation: COMPATIBLE

Vitamin D:

• Interaction Mechanism:
  • No direct interaction
  • Both beneficial for overall health
• Recommendation: SAFE

B-Complex Vitamins:

• Interaction Mechanism:
  • SYNERGISTIC (B3/niacin is NAD+ precursor; other B vitamins support methylation, energy metabolism)
  • High NAD+ → high NAM production → methylation via NNMT → may deplete SAMe
  • B vitamins (especially folate, B12, B6) support methylation cycle
• Recommendation: HIGHLY COMPATIBLE; B-complex recommended with high-dose NAD+

TMG (Trimethylglycine/Betaine):

• Interaction Mechanism:
  • SYNERGISTIC (TMG donates methyl groups; supports methylation cycle)
  • High NAD+ → high NAM → methylation demand → TMG beneficial
• Recommendation: HIGHLY COMPATIBLE; consider TMG 1-2 g/day with high-dose NAD+

Creatine:

• Interaction Mechanism:
  • SYNERGISTIC (creatine supports ATP/phosphocreatine system; NAD+ supports mitochondrial ATP production)
  • Creatine also uses SAMe for methylation (like NAM) → both may increase methylation demand
• Recommendation: COMPATIBLE; ensure adequate B vitamin/TMG intake

Caffeine:

• Interaction Mechanism:
  • Caffeine ↑ lipolysis; NAD+ supports fat oxidation
  • Synergistic for fat loss
• Recommendation: COMPATIBLE

Summary: Drug Interaction Risk Stratification

Key Takeaways:

1. Oral NR/NMN at therapeutic doses are generally safe with most medications
2. IV NAD+ requires more caution (high doses, rapid exposure)
3. Greatest concerns: Active cancer treatment, immunosuppression
4. Most beneficial combinations: Metabolic drugs (metformin, GLP-1), hormones (TRT, GH), longevity supplements (resveratrol, quercetin)
5. Methylation support important with high-dose NAD+ (B vitamins, TMG)

Regulatory Status & Safety Oversight

NR:

• FDA GRAS status (Generally Recognized As Safe)
• Allowed in dietary supplements
• Quality varies by manufacturer; third-party testing recommended

NMN:

• Initially excluded by FDA (Nov 2022) due to drug exclusion clause (MetroBiotech IND application)
• REVERSED Sept 2025: FDA declared NMN lawful in dietary supplements
• Controversy highlights regulatory uncertainty

IV NAD+:

• NOT FDA-approved for any indication
• Administered in wellness clinics as "nutritional IV therapy"
• Lack of oversight raises quality and safety concerns

Monitoring Recommendations (If Using Long-Term)

Baseline:

• Comprehensive metabolic panel (CMP)
• Liver function (ALT, AST)
• Renal function (creatinine, eGFR)
• Fasting glucose, lipid panel
• Optional: Baseline NAD+ level

Follow-Up:

• Repeat labs every 6-12 months
• Age-appropriate cancer screening
• Monitor for new symptoms (fatigue, GI changes)

Adverse Event Reporting:

• Report suspected adverse reactions to FDA MedWatch

References:

• NAD IV Therapy Safety & Side Effects - Peach IV
• Clinical Evidence for Targeting NAD - PMC
• NAD Therapy Side Effects - Drip Hydration

Storage & Stability

NR Powder/Capsules:

• Store in cool, dry place (<25°C)
• Protect from moisture and light
• Shelf life: 24 months (sealed)

NMN Powder/Capsules:

• More sensitive to degradation than NR
• Store in refrigerator (2-8°C) or freezer (-20°C) for maximum stability
• Moisture-sensitive; use desiccant packs
• Shelf life: 12-18 months (refrigerated)

IV NAD+ Solutions:

• Prepared fresh for each infusion
• Sterile normal saline or LR as diluent
• Use within 24 hours of preparation

Product Cross-Reference

Core Peptides: NOT AVAILABLE (WebFetch returned image data; no product listing found)

Alternative Suppliers:

• NR: Numerous brands (Tru Niagen, Life Extension, Thorne)
• NMN: Multiple suppliers post-FDA reversal

Stacking Insights

• ience about NM or NAD+. Let me give you some straight facts on this so you guys don't get inundated with [ __ ] from more people. NAD+ is the universal energy currency inside every cell.
• gevity peptides on the planet. Period. Again, I'll say it over and over again. I will go toe-to-toe with anybody that challenges me on that.

References & Citations

1. Nicotinamide adenine dinucleotide - Wikipedia
2. NAD+ metabolism and cellular processes - PMC
3. NAD+ and Sirtuins in Aging - PMC
4. NAD+ repletion improves mitochondrial function - Science
5. What is really known about NR - Science Advances
6. NAD+ Precursors NMN and NR - PMC
7. Dietary Supplementation With NAD+ - PMC
8. Oral NMN Increases NAD+ - PMC
9. Pharmacology of NAD+ Precursors - PMC
10. NR is orally bioavailable - Nature Communications
11. FDA Reverses NMN Decision - AboutNAD
12. NAD IV Therapy Safety - Peach IV

Document Version: 1.0 Last Updated: December 2024 Classification: Coenzyme / Metabolic Cofactor